BET Inhibitors
Bromodomain and Extra-Terminal domain (BET) proteins, comprising BRD2, BRD3, BRD4, and BRDT, function as crucial epigenetic readers that recognize and bind to acetylated lysine residues on histones and other proteins. Through their tandem bromodomains, BET proteins act as scaffolds, recruiting transcriptional machinery and chromatin remodeling complexes to active regulatory elements such as enhancers and promoters. This recruitment drives the transcription of key genes involved in cell proliferation, survival, and differentiation. BRD4, in particular, is a well-studied member, playing a pivotal role in maintaining super-enhancer-driven transcription of oncogenes like MYC and BCL2, which are frequently dysregulated in various cancers. The BET family's involvement extends beyond oncology, with roles identified in inflammatory diseases, cardiovascular conditions, and viral infections, underscoring their broad impact on cellular homeostasis and disease pathogenesis. The therapeutic potential of BET inhibition has spurred intense research and drug development efforts. BET inhibitors are small molecules designed to competitively bind to the acetyl-lysine binding pocket of BET bromodomains, thereby displacing BET proteins from chromatin and disrupting their transcriptional regulatory functions.
This leads to the downregulation of BET-dependent gene expression, including critical oncogenes. Numerous BET inhibitors have entered clinical trials across a spectrum of cancers, particularly hematological malignancies such as acute myeloid leukemia (AML), multiple myeloma, and lymphoma, as well as solid tumors. Examples include OTX015 (birabresib), ABBV-075, ZEN-3694, and CPI-0610. While none have yet received regulatory approval, many have demonstrated promising preclinical and early clinical activity, often leading to disease stabilization or partial responses. Preclinical studies are also exploring their utility in non-oncology indications, such as inflammation and fibrosis. Most current BET inhibitors are pan-BET inhibitors, targeting all BET family members, although efforts are underway to develop more selective inhibitors for individual bromodomains or specific BET proteins to potentially reduce off-target effects. Key challenges in BET inhibitor development include managing dose-limiting toxicities, such as thrombocytopenia and gastrointestinal disturbances, which are common across the class.
Furthermore, resistance mechanisms can emerge, often involving compensatory upregulation of MYC or activation of alternative signaling pathways. To address these challenges and enhance therapeutic efficacy, combination therapy strategies are being rigorously investigated. BET inhibitors are being combined with a wide array of agents, including chemotherapy, other targeted therapies (e.g., PARP inhibitors, CDK4/6 inhibitors, BCL2 inhibitors), and immune checkpoint inhibitors, aiming for synergistic effects and overcoming resistance. A notable advancement in the field is the development of PROTAC (Proteolysis-Targeting Chimera) degraders for BET proteins. These molecules hijack the cell's ubiquitin-proteasome system to induce catalytic degradation of BET proteins rather than just inhibiting their function, offering a potentially more profound and sustained therapeutic effect. Research tool compounds like JQ1 have been instrumental in elucidating BET biology and validating BET proteins as drug targets, paving the way for clinical candidates. The ongoing exploration of BET inhibitors, including PROTACs and combination regimens, continues to position them as a significant class of epigenetic therapeutics.
